Three Phase 3 wins in one quarter is unusual by any measure, and Definium Therapeutics now has exactly that behind DT120 ODT. The company reported positive topline results from both the Voyage and Panorama studies in generalized anxiety disorder this quarter, adding to the previously reported Emerge win in major depressive disorder. The Voyage result, drawn from 214 participants randomized 1:1, showed a 5.4-point placebo-adjusted improvement on the Hamilton Anxiety Rating Scale at 12 weeks (p<0.0001, Cohen’s d=0.81). Panorama, with 245 participants in a three-arm design, produced a 5.1-point separation (p<0.0001, Cohen’s d=0.64). Both studies met their primary and all key secondary endpoints with no drug-related serious adverse events and no suicidality signal observed in Part A of each study.
The regulatory setup strengthens the case further. Following Emerge, the FDA granted Breakthrough Therapy Designation for DT120 ODT in MDD, a designation that, according to one analysis of psychiatric approvals from 2012 through 2024, a designation granted to a small minority of approved psychiatric drugs. Definium now targets an NDA filing in the first half of 2027. That filing will draw on a dataset spanning previously reported Phase 2 results, plus three consistent Phase 3 readouts across two indications. The ongoing Phase 3 Ascend study in MDD, targeting roughly 165 participants, is expected to deliver topline data in 2027 as well.
Definium is also extending the program in two directions simultaneously. The Phase 3 Haven study in PTSD is planned for 2027 initiation, enrolling approximately 200 participants with the Clinician-Administered PTSD Scale for DSM-5 at Week 8 as the primary endpoint. And a separate compound, DT402, produced its first human data in a five-person, single-dose, open-label Phase 2a study in adults with autism spectrum disorder. The findings were exploratory and not powered for statistical conclusions, but improvements in socialization and reductions in rigidity prompted plans for a 2027 multi-dose study. The company held approximately $1.05 billion in cash, equivalents, and investments as of September 30, leaving it funded well into the NDA window.
The number to watch now is the Cohen’s d effect size that emerges from the Ascend MDD readout in 2027. GAD produced effect sizes of 0.81 and 0.64 across two trials; a comparable or stronger signal in MDD, where the Breakthrough designation already applies, would materially shape the label negotiation that follows an NDA submission.
Source link: https://www.sec.gov/Archives/edgar/data/1813814/000119312526453595/dftx-20261109.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
